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Abstract
Background: Forkhead box P3(FOXP3) is known as the optimum maker for regulatory T cells(Tregs), which are
conventionally thought to induce immune tolerance to disturb the antitumor immunity. However, the research on
the prognostic significance of tumor-infiltrating FOXP3+ Tregs in breast cancer is still limited and the results are
controversial.
Methods: We searched for studies in PubMed, EMBASE and Web of Science prior to January 2015. The correlation
between FOXP3+ tumor-infiltrating lymphocytes(TILs) and breast cancer prognosis was analyzed. The meta-analysis
was performed using STATA 11.0. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) were used to
estimate the degree of the association between FOXP3+ TILs and prognosis of breast cancers, while relative ratios
(RRs) were used to evaluate the relationship between FOXP3+ TILs and clinicopathological features of breast
cancers.
Result: A total of 15 studies comprising 8666 breast cancer patients met the inclusion criteria. Our results showed
that higher FOXP3+ TILs level was significantly associated with poor prognosis in terms of overall survival (OS)
(pooled HR:1.60, 95 % CI:1.06–2.42; P < 0.05). We found that breast cancer with higher FOXP3+ TILs level was
positively correlated with c-erbB-2 positive status (pooled RR:1.52, 95 % CI:1.32–1.75; P < 0.05), lymph node positive
status(pooled RR:1.17, 95 % CI:1.04–1.32; P < 0.05) while there was a negative association with ER positive
status(pooled RR:0.65, 95 % CI:0.56–0.76; P < 0.05) and PR positive status(pooled RR:0.66, 95 % CI:0.51–0.87; P < 0.05).
Conclusion: The present results of meta-analysis showed that higher FOXP3+ TILs level in patients with breast
cancer led to poor overall survival (OS) and was significantly associated with c-erbB-2 status, lymph node status, ER
status and PR status. FOXP3+ TILs level is a promising prognostic factor in breast cancer.
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Background
Breast cancer is one of the most common malignancies
and expected to account for 29 % of all newly diagnosed
cancers and 14 % of all cancer deaths in women world-
wide. Though death rate for female breast cancer has de-
creased by 35 % from peak rate, it is still the leading
cause of cancer death in women from aged 20 to 59 years
[1]. In most cancers, including breast cancer [2–4], infil-
trating of FOXP3+ regulatory TILs have been reported
to be associated with worse clinical outcome. However,
MJM Gooden et al. reported that FOXP3+ regulatory
TILs were not linked to the overall survival in cancers
[2].
FOXP3 is a forkhead box transcription factor contain-
ing a DNA-binding domain that suppresses the expres-
sion of target genes [3]. The regulatory T lymphocytes
(Tregs), subpopulation of CD4(+) T lymphocytes, is an
important obstacle in antitumor immunity by suppres-
sion of tumor antigen reactive T lymphocytes [4–6]. The
transcription factor FOXP3, known as the most specific
marker of Tregs [7–9], plays a crucial role in the devel-
opment and function of Tregs,. FOXP3 is constitutively
expressed in the nucleus of human Tregs [10, 11]. Sev-
eral studies showed that higher FOXP3+ Tregs indicated
poor prognosis [12–14] in patients with breast cancer
while some revealed no direct association between them
[15]. In short, studies to confirm the clinical significance
of FOXP3+ TILs in breast cancer are still insufficient
and the prognostic value still lacks assessment, especially
in different molecule types of breast cancer. Therefore,
we find it necessary to further assess the association be-
tween tumor-infiltrating FOXP3+ Tregs and prognosis
of breast cancer by conducting a meta-analysis with a
large sample size (N = 8666). The relationship between
FOXP3+ TILs and several clinicopathological features of
breast cancer was also evaluated.
Methods
Literature search strategy
We searched PubMed, EMBASE and Web of Science for
relevant studies before January 2015, using the terms:
“FOXP3 lymphocytes” or “FOXP3 regulatory T cell” or
“FOXP3 TIL” or “FOXP3 tumor-infiltrating lympho-
cytes” and “breast cancer”. We searched the references
of all retrieved publications and conference proceedings
again to identify additional relevant studies.
Selection criteria
The studies included in our meta-analysis should meet
following criteria: [1] the study must be conducted on
the human beings; [2] the study must assess the associ-
ation between FOXP3+ TILs level and the prognosis of
breast cancer; [3] The count of FOXP3+ TIL include ei-
ther tumor bed or tumor peripheral lymphocytes [4] the
study must contain sufficient published data to deter-
mine an estimate of hazard ratio(HR) and a 95 % confi-
dence interval(95 % CI); [5] original research article
must be published in English.
Data extraction and quality assessment
Data were extracted from the eligible studies by two in-
vestigators independently. Discrepancies were resolved
by consensus. The following information was abstracted
from all included publications: author, year of publica-
tion, country of study, tumor type, median follow-up
time, cut-offs for positive expression, number of TILs-
low and TILs-high patients, number of patients with dif-
ferent clinicopathological features, outcome of analysis
(including HRs and 95 % CIs).
Quality assessment was conducted for each of the in-
cluded studies using the Newcastle-Ottawa quality as-
sessment scale [16]. The score assessed eight items on
methodology that were categorized into three dimen-
sions, including selection, comparability and outcome.
Interpretation of the scale is performed by awarding
“stars”, for high-quality element. The studies with 6
scores or more were regarded as high-quality ones in the
scale.
Statistical analysis
Survival outcome data were synthesized using the HR
and its 95 % CI to assess the impact of higher FOXP3+
TILs level on the overall survival (OS) and relapse free
survival (RFS) of patients with breast cancer. Several in-
cluded studies have provided HRs and their 95 % CIs,
which we extracted directly from the papers. Otherwise,
we calculated the HRs and 95 % CIs from the Kaplan-
Meier survival curve using the software Engauge
Digitizer version 4.1 (http://digitizer.sourceforge.net/)
[17, 18]. The relative ratio (RR) was used to evaluate the
association between FOXP3+ TILs and clinicopathologi-
cal features of breast cancer (including tumor cate-
gory(T), lymph node category(N), c-erbB-2, ER and PR
status). Heterogeneity across studies was evaluated using
a Chi-square-based Q statistical test [19], and the I2
value was used to quantify the heterogeneity [20]. The
random-effect model (the DerSimonian and Laird-
method) was used for meta-analysis [21]. Publication
bias was assessed using Begg’s test [22]. In addition, sen-
sitivity analysis was performed to examine the stability
of the pooled results. The statistical analyses were con-
ducted using STATA11.0. All P values were two-sided,
and P < 0.05 was considered to be statistically significant.
Results
Study selection and characteristics
As shown in Fig. 1, a total of 284 articles were initially
retrieved from the above databases using the search
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strategy described above. From candidate publications fol-
lowing exclusions, our search found 15 studies satisfying
the inclusion criteria. The main characteristics of included
studies were presented in Additional file 1: Table S1. An
additional file shows this in more detail (see Additional
file 1). These studies were published from 2006 to 2014
and total 8666 patients with breast cancer were enrolled.
Individual sample size ranged from 72 to 3992 (mean
578). These studies were conducted in nine counties (the
United Kingdom, the United States, Turkey, Korea, China,
Canada, Japan, Australia and France). Overall, the
included studies in meta-analysis were of high quality, six
studies scored 8, six studies scored 7 and three studies
scored 6.
FOXP3+ TILs level and prognosis of breast cancers
We pooled overall survival (OS) and relapse free survival
(RFS) to assess the impact of FOXP3+ TILs level on the
prognosis of breast cancers. 8 studies evaluated the rela-
tionship between FOXP3+ TILs and OS [12, 13, 23–28].
The pooled HR is 1.60(95 % CI:1.06–2.42; P < 0.05)
(Fig. 2). It indicated that higher FOXP3+ TILs level was
Fig. 1 Flow diagram showing the study selection procedure
Fig. 2 Forest plot of the hazard ratio (HR) for the association of FOXP3+ level with overall survival (OS) in breast cancer patients
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statistically related to a poor OS rate. 5 studies
assessed the association between FOXP3+ TILs and
RFS [14, 23, 28–30]. The pooled HR is 1.06(95 % CI:
0.64 ~ 1.74; P > 0.05) (Fig. 3) which indicated that
FOXP3+ TILs level was not correlated with RFS of
breast cancers.
Correlation of FOXP3+ TILs level with clinicopathological
parameters
The meta-analysis also estimated the association be-
tween FOXP3+ TILs level and certain clinicopathologi-
cal parameters. As shown in Fig. 4c and e, breast
cancers with higher FOXP3+ TIL level were positively
correlated with c-erbB-2 status(pooled RR:1.52, 95 %
CI:1.32–1.75; P < 0.05), lymph node status(pooled
RR:1.17, 95 % CI:1.04–1.32; P < 0.05). Compared with
ER-negative breast cancers, ER-positive breast cancers
showed lower FOXP3+ TILs level (pooled RR:0.65, 95 %
CI:0.56–0.76; P < 0.05) (Fig. 4a). Similar phenomenon
was observed in PR-positive breast cancers(pooled
RR:0.66, 95 % CI:0.51–0.87; P < 0.05) (Fig. 4b). This indi-
cated that in c-erbB-2 positive or lymph node positive
breast cancers, there was higher FOXP3+ TILs level. On
the other hand, ER positive or PR positive breast cancers
were accompanied with lower FOXP3+ TILs level. In
addition, we found no association between higher
FOXP3+ TIL level and tumor category of breast cancers
(pooled RR:1.08, 95 % CI:0.98–1.19; P > 0.05) (Fig. 4d).
Publication bias
Begg’s test indicated negligible publication bias after
assessing the funnel plot for the studies included in our
meta-analysis (Figs. 5 and 6).
Sensitivity analysis
In the sensitivity analysis, the influence of each study on
the pooled HR of OS and RFS was assessed by repeating
the meta-analysis while sequentially omitting each study.
The results showed that the association did not change
significantly after removing any study. An additional
shows this in more detail (see Additional file 2).
Discussion
FOXP3+ Tregs, part of tumor-infiltrating lymphocytes
(TILs), play a critical role in immune tolerance and defi-
ciency of anti-tumor immunity [4–6]. Several studies re-
vealed that FOXP3+ TILs level had a negative impact on
the prognosis of breast cancer [14, 31, 32]. However, the
exact prognostic significance was still unclear and the
information was limited. In our meta-analysis, 15 eligible
articles were included which evaluated the association
between FOXP3+ TILs level and prognosis of breast
cancer. Ezzeldin M et al. and X. Yu et al. have reported
that TILs were associated with prognosis of breast can-
cer in their meta-analysis [33, 34]. However, TILs in our
meta-analysis referred to FOXP3+ TILs specifically.
Thus, our meta-analysis seems more applicable in clin-
ical practice. The pooled results showed that a higher
density of FOXP3+ lymphocytes in tumor tissue was a
promising prognostic factor for OS of breast cancers.
However, the FOXP3+ TILs level was proved not having
significantly higher risk of relapse. These results are po-
tentially important for prognostic and treatment reasons.
FOXP3 is the most specific marker of CD4 + CD25+
Tregs and appears to be critical for the development and
function of Tregs derived from thymus [8, 35, 36].
Tumor-infiltrating lymphocytes(TILs) in our meta-
analysis refer to the lymphocytes either infiltrating in
tumor bed or tumor periphery. FOXP3+ Tregs was an
important group of TILs and Udaya K et al. has reported
that FOXP3 + Tregs prevalence was 20.2 % in TILs of
breast adenocarcinoma [37]. FOXP3+ Tregs suppressed
the function of effector T cells to destroy maintenance
of immune balance which resulted in the escape of
tumor immunological surveillance [8, 38]. FOXP3+
Tregs secreted TGF-β, which indicated that the
Fig. 3 Forest plot of the hazard ratio (HR) for the association of FOXP3+ level with relapse free survival (RFS) in breast cancer patients
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suppression of anti-tumor immunity of FOXP3+ Tregs
may be cytokine-dependent [39]. FOXP3+ Tregs also se-
creted IL-10 to suppress Th1/2 cell proliferation via in-
hibition of IL-2 and down-regulating MHC class II on
monocytes [40, 41]. In addition, FOXP3+ Tregs inhibit
the proliferation and IFN-y secretion by activated CD8+
T cells and CD4+ helper T cells [37]. FOXP3+ Tregs ex-
press CD39/CD73 that generates adenosine, which can
down-modulate immune function [42, 43]. These may
account for the poor overall survival in breast cancers
with higher FOXP3+ TILs level. Nevertheless, other im-
mune cells might have impact on the prognosis of breast
cancer. Natural killer (NK) cells contributed to a patho-
logical complete response (pCR) in breast cancers fol-
lowing neoadjuvant chemotherapy [44]. Lymphocytes
infiltrating human breast cancers showed lower levels of
NK-cell activity [45]. Tiainen S et al. reported that
higher level of infiltrated macrophage, especially M2-
like, correlated with poor outcome in breast cancer [46].
Thus, a more effective model needs to be established to
Fig. 4 Forest plot assessing the FOXP3+ TILs and clinicopathological features such as ER status (a), PR status (b), c-erbB-2 status (c), tumor cat-
egory (d), lymph node category (e)
Fig. 5 Begg’s test results of the OS (a) and RFS (b)
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predict the prognosis of breast cancer. No association
was observed between higher FOXP3+ TILs level and
RFS of breast cancers in our meta-analysis.
In addition, we investigated the association between
FOXP3+ TILs and some clinicopathological parameters
of breast cancer. Significant positive correlations were
found between high FOXP3+ TILs with c-erbB-2 status
and lymph node status while negative correlations with
ER and PR status. The result implied that ER+ breast
cancer was accompanied with lower FOXP3+ TILs. N R
West et al. [30] demonstrated a similar phenomenon
with our result. Another point worth attention was that
in c-erbB-2+ breast cancer, there was a significantly
higher level of FOXP3+ TILs, also reported by Sahar
M. A et al. [15].
However, there are still some limitations in our meta-
analysis. Firstly, the included studies were restricted
within English articles and completed in 9 countries,
which may result in potential publication bias while
Begg’s test showed no evidence. Secondly, heterogeneity
was found in the meta-analysis, which may be due to
different cutoff values of FOXP3+ TILs in the included
studies. Though the detecting technology of FOXP3+
TILs in included studies was all immunohistochemistry
(IHC), the different antibody type and antibody concen-
tration may contribute to the heterogeneity of included
studies. Thirdly, the HRs and 95 % CIs extracted from
survival curves may be less reliable than those directly
obtained from the articles.
Conclusion
Despite the limitation listed above, our meta-analysis
based on currently published articles indicted that higher
FOXP3+ TILs level was inclined to poor OS while no
significant association was observed with RFS. Accord-
ingly, FOXP3+ TILs can be considered as a promising
therapeutic target.
Additional files
Additional file 1: Table S1. Characteristics of the included studies.
(DOCX 39 kb)
Additional file 2: Sensitivity analysis of forest plots included in our
meta-analysis. (PDF 43 kb)
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